Moderna Inc. (NASDAQ:MRNA)

The capital structure exhibits a strong preference for equity financing, maintaining a consistently low leverage profile over the six-year period. Despite significant fluctuations in the absolute values of both liabilities and equity, the overall risk profile associated with debt remains minimal.

Stockholders' Equity Evolution

Equity experienced a period of rapid expansion starting in 2020, rising from US$ 2,561 million to a peak of US$ 19,123 million by December 31, 2022. This represents a substantial increase in the capital base. A subsequent contraction occurred in 2023, with equity decreasing to US$ 13,854 million.

Financing Lease Liabilities Analysis

Lease obligations remained low and stable between 2018 and 2019 but increased sharply starting in 2020. Liabilities peaked at US$ 1,073 million in 2022 before declining significantly to US$ 575 million by the end of 2023, indicating a reduction in leased asset obligations.

Debt to Equity Ratio Performance

The debt to equity ratio remained remarkably stable, fluctuating within a narrow range between 0.03 and 0.06. The ratio peaked at 0.06 in 2022, coinciding with the maximum level of lease liabilities, and returned to 0.04 in 2023. This stability indicates that the growth in liabilities was proportionally matched or exceeded by the growth in equity, ensuring that leverage did not increase significantly during the period of rapid scaling.